炎性乳腺癌临床病理特征与化疗疗效及预后的相关性分析

发布时间：2018-04-25 21:14

本文选题：炎性乳腺癌 + 化疗　；参考：《中国肿瘤临床》2017年16期

【摘要】：目的:探讨炎性乳腺癌(inflammatory breast cancer,IBC)患者临床病理特征与新辅助化疗疗效及预后的相关关系。方法:回顾性分析天津医科大学肿瘤医院2010年1月至2013年12月收治且接受新辅助化疗的81例IBC患者临床资料,应用单因素及多因素统计学方法分析其临床病理特征对化疗疗效及预后的影响。结果:所有患者3年总生存(OS)率和无病生存(DFS)率分别为53.1%和37.0%,患者接受新辅助化疗后的病理完全缓解(pathologic complete response,pCR)率为13.6%(11/81)。新辅助化疗后是否达到pCR与患者的病理类型和分子分型有关(P0.05),但获得pCR并不会改善其预后(P0.05),而IBC患者的术前淋巴结分期是OS和DFS的独立影响因素(均P0.05),新辅助化疗方案和淋巴管癌栓情况是影响患者DFS的独立因素(P0.05)。结论:IBC的临床病理特征影响患者对化疗的敏感性,同时通过对术前淋巴结分期和淋巴管癌栓状态的评估,可以预测疾病的预后,合理使用新辅助化疗方案,以期达到最佳的治疗效果。
[Abstract]:Objective: to investigate the relationship between the clinicopathological features of inflammatory breast cancer patients and the efficacy and prognosis of neoadjuvant chemotherapy. Methods: the clinical data of 81 patients with IBC who received neoadjuvant chemotherapy from January 2010 to December 2013 in Tianjin Medical University Oncology Hospital were retrospectively analyzed. Univariate and multivariate statistics were used to analyze the influence of clinicopathological features on the curative effect and prognosis of chemotherapy. Results: the total survival rate and disease-free survival rate of all patients were 53.1% and 37.0, respectively. The rate of pathologic complete responsepCRs after neoadjuvant chemotherapy was 13.6% and 11.81%, respectively. Whether or not to reach pCR after neoadjuvant chemotherapy is related to the pathological type and molecular type of patients. However, obtaining pCR does not improve the prognosis of IBC patients. The preoperative lymph node staging of IBC patients is an independent factor of OS and DFS (all P 0.05, neoadjuvant). The therapeutic regimen and lymphatic thrombus were independent factors affecting DFS in patients (P 0.05). Conclusion the clinicopathological features of WIBC influence the sensitivity of the patients to chemotherapy. By evaluating the preoperative lymph node staging and lymphatic thrombus status, the prognosis of the disease can be predicted and the neoadjuvant chemotherapy regimen can be used reasonably. In order to achieve the best therapeutic effect.
【作者单位】：天津医科大学肿瘤医院乳腺二科国家肿瘤临床医学研究中心天津市肿瘤防治重点实验室乳腺癌防治教育部重点实验室;河北大学附属医院乳腺外科;
【分类号】：R737.9

【相似文献】